Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | DHFR | P00374 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121930 | 0.81 | AURKA (0.66) | KMT2AMEN1LMNAAURKADHFR | |
| Sulfadiazine SCHEMBL30080807 | 0.77 | LMNA (1.00) | KMT2AMEN1LMNAAURKADHFR | |
| SCHEMBL12306892 | 0.77 | ALDH1A1 (0.87) | KMT2AMEN1LMNAAURKADHFR | |
| Sulfadiazine SCHEMBL24176 | 0.77 | LMNA (1.00) | KMT2AMEN1LMNAAURKADHFR | |
| Sulfadiazine SCHEMBL10422849 | 0.77 | LMNA (1.00) | KMT2AMEN1LMNAAURKADHFR | |
| Sulfadiazine SCHEMBL28350872 | 0.76 | LMNA (0.90) | KMT2AMEN1LMNAAURKADHFR | |
| Sulfadiazine SCHEMBL28728783 | 0.76 | LMNA (0.82) | KMT2AMEN1LMNAAURKADHFR | |
| Sulfadiazine SCHEMBL11611850 | 0.76 | LMNA (0.96) | KMT2AMEN1LMNAAURKADHFR | |
| Sulfadiazine SCHEMBL34517 | 0.76 | LMNA (0.96) | KMT2AMEN1LMNAAURKADHFR | |
| Sulfadiazine SCHEMBL16860643 | 0.76 | LMNA (0.96) | KMT2AMEN1LMNAAURKADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | SIGA TECHNOLOGIES, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | EIF2AK2, HAVCR2, SNRPE | KMT2A 3347/4885MEN1 3401/4885LMNA 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.